Table 2.

Results of Multivariate Analysis of Overall Survival in the Intention-to-Treat Population.^*

Variable	Model Fit		Hazard Ratio for Death (95% CI)
	Coefficient	P Value
Treatment: abiraterone acetate vs. placebo	−0.4±0.09	<0.001	0.66 (0.55–0.78)
ECOG score: 0 or 1 vs. 2	−0.9±0.12	<0.001	0.40 (0.32–0.50)
Pain: absent vs. present	−0.4±0.09	<0.001	0.67 (0.56–0.79)
Previous chemotherapy regimens: 1 vs. 2	−0.2±0.09	0.006	0.78 (0.66–0.93)
Evidence of progression: PSA concentration only vs. radiographic findings	−0.3±0.10	0.01	0.78 (0.64–0.94)

^*Data on patients who had not died by the time of analysis were censored on the last date the patient was known to be alive or was available for follow-up. Each test was carried out at a significance level of 0.05. CI denotes confidence interval, ECOG Eastern Cooperative Oncology Group, and PSA prostate-specific antigen.